Recent developments include clinical trial advancements, strategic acquisitions, and capital raising activities that reflect ongoing execution in clinical development and corporate growth.

• TransCode's lead candidate TTX-MC138 entered a Phase 2a clinical trial as part of the Quantum Leap PRE-I-SPY platform in December 2025 [N2].
• The company acquired Polynoma from CK Life Sciences in October 2025, expanding its pipeline [N3].
• TransCode announced a $10 million stock and warrant offering in March 2025 to support operations and development [N5].
• The company raised $8 million in a private placement as of April 2026, providing additional capital [N1].
• TransCode regained Nasdaq listing compliance in early 2025, resolving prior compliance issues [N8].
• The lead candidate advanced to cohort 3 in an ongoing Phase 1 study as of February 2025, indicating clinical progress [N7].
• The company advanced its Phase I trial of RNA cancer therapy in March 2025, demonstrating ongoing clinical development [N6].

The company has demonstrated clinical progress with its lead candidate TTX-MC138 advancing into Phase 2a trials within a collaborative platform, indicating potential validation of its RNA therapeutic approach. Strategic acquisition of Polynoma expands its pipeline and capabilities. The company has successfully raised capital through multiple offerings, supporting continued development and operations. Regaining Nasdaq compliance reflects improved corporate governance and regulatory standing. Experienced leadership with deep biotech industry knowledge supports strategic execution. Strong liquidity ratios provide a buffer for ongoing clinical and operational activities.

The company reported a significant net loss of $34.7 million for the fiscal year ended 2025, reflecting high operating expenses typical of clinical-stage biotech firms without product revenue. The business is dependent on successful clinical trial outcomes and regulatory approvals, which carry inherent risks and uncertainties. Ongoing capital raising is necessary to fund operations, which may lead to dilution. The company’s financial and operational performance is subject to market, regulatory, and competitive risks common in the biotechnology sector. Any delays or failures in clinical development or financing could adversely impact the company’s prospects.

Transcode Therapeutics’ moat is primarily based on its proprietary RNA-based therapeutic platform targeting oncology indications, which is supported by clinical trial progress and strategic acquisitions such as Polynoma. The company’s leadership team has extensive industry experience, which supports execution in a complex biotech environment. The company’s participation in collaborative clinical platforms like Quantum Leap PRE-I-SPY may provide access to innovative trial designs and partnerships. However, as a clinical-stage biotech company, the moat is contingent on successful clinical development, regulatory approvals, and the ability to secure ongoing financing. The company’s strong liquidity position as of the end of 2025 provides operational runway to advance its pipeline.

• Clinical Development Risk: The company’s lead candidate and pipeline are in early clinical stages, and failure to demonstrate safety and efficacy could materially impact the business.
• Financing and Dilution Risk: The company relies on capital raises, including convertible notes and equity offerings, which may dilute existing shareholders and depend on market conditions.
• Regulatory Risk: The company must obtain regulatory approvals for its therapies, which involves complex and uncertain processes that could delay or prevent commercialization.
• Market and Competitive Risk: The biotechnology sector is highly competitive with rapid technological changes; competitors may develop superior therapies.

• Transcode Therapeutics, Inc. is a Delaware corporation headquartered in Boston, Massachusetts.
• The company is listed on The Nasdaq Capital Market under the ticker RNAZ.
• As of April 27, 2026, the company had 916,968 shares of common stock outstanding.
• The company operates in the biotechnology/pharmaceutical sector focusing on RNA-based cancer therapies.
• Philippe P. Calais, PharmD, PhD, has been CEO since October 2025 and Chairman of the Board since January 2021, with extensive biotech industry experience.
• Thomas A. Fitzgerald serves as Chief Financial Officer and Director, having also served as interim CEO from January 2024 to October 2025.
• The Board includes experienced directors with backgrounds in biotech and finance.
• The company’s lead clinical candidate is TTX-MC138, an RNA cancer therapy currently advancing through clinical trials.
• TTX-MC138 entered Phase 2a clinical trial as part of the Quantum Leap PRE-I-SPY platform as of December 2025.
• The company acquired Polynoma from CK Life Sciences in October 2025.
• Transcode has conducted multiple financing rounds including a $10 million stock and warrant offering in March 2025 and an $8 million private placement in April 2026.
• The company regained Nasdaq listing compliance in early 2025 after prior non-compliance issues.
• Financial figures from the 10-K/A for the fiscal year ended December 31, 2025, include cash and equivalents of $17.8 million, current assets of $22.0 million, and current liabilities of $3.5 million, resulting in a current ratio of 6.29 and a cash ratio of 5.1.
• Net loss for the fiscal year ended December 31, 2025, was $34.7 million with basic and diluted EPS of -$52.59 per share.
• The company has a Standby Equity Purchase Agreement (SEPA) with Yorkville providing access to capital through convertible notes and equity sales subject to ownership limits.
• The company’s business model centers on developing RNA-based therapeutics for oncology indications, with clinical development and strategic acquisitions as key components.
• The company’s executive compensation and governance disclosures are detailed in the latest 10-K/A filing.
• The company’s liquidity position as of December 31, 2025, is strong with significant cash relative to current liabilities, supporting ongoing operations and clinical development.